Clinical trials: Glial Tumor
Glioblastoma
89Zr-RO5323441 PET Imaging in Glioblastoma
The research the investigators propose is a molecular imaging study of RO5323441, an antibody against placental growth factor (PlGF) in patients with recurrent GBM treated with bevacizumab, a drug against vascular endothelial…
- Trial name
- NCT01622764
- Testing
- Molecular imaging with 89Zr-RO5323441
- Where
- Netherlands
- Sponsor
- University Medical Center Groningen
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Glioblastoma, Radiotherapy
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy
No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy.
- Conditions
- Glioblastoma, Radiotherapy, Chemotherapy
- Trial name
- SPECTROBEVA (NCT03144167)
- Testing
- Analysis of spectroscopic biomarkers of proliferation for six-month survival
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
Background: The radiological follow-up of diffuse gliomas is challenged by the difficult distinction of true progression from treatment-related changes.
- Trial name
- APPEAR (NCT07159607)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- LMU Klinikum
Brain and Central Nervous System Tumors
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who…
- Trial name
- NCT00002971
- Testing
- O6-benzylguanine
- Where
- 9 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival.
- Trial name
- NCT07091864
- Testing
- Best Practice, Biospecimen Collection, Dietary Intervention
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- Mayo Clinic
Medulloblastoma, Neuroectodermal Tumor
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers.
- Trial name
- Re-MATCH (NCT01326104)
- Testing
- TTRNA-xALT, TTRNA-DCs
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Florida
Astrocytic Tumors, Glioblastoma Multiforme
Phase I Study of Safety and Immunogenicity of ADU-623
This is a study for patients with brain tumors called astrocytic tumors. The study will enroll patients who have received standard treatment. The study will test a vaccine called ADU-623.
- Conditions
- Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
- Trial name
- NCT01967758
- Testing
- Cohort 1, Cohort 2, Cohort 3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Providence Health & Services
Glioblastoma, Recurrent Glioblastoma
ASP8374 + Cemiplimab in Recurrent Glioma
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Trial name
- NCT04826393
- Testing
- ASP8374, cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma Multiforme
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth).
- Trial name
- NCT00038493
- Testing
- Temozolomide and SCH66336
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Medulloblastoma
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
- Trial name
- PNOC020 rMB (NCT07492316)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Glioma Glioblastoma Multiforme
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression and are candidates for a surgical resection according to standard of care may be eligible for this study.
- Trial name
- Axumin (NCT03990285)
- Testing
- Axumin, Intravenous Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ali Nabavizadeh
Glioma, Malignant, Embryonal Tumor
Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas
The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases.
- Conditions
- Glioma, Malignant, Embryonal Tumor, Medulloblastoma, Ependymoma
- Trial name
- BZKF-AYA (NCT06323408)
- Testing
- Tissue, blood, cerebrospinal-spinal fluid
- Volunteers
- 72 people
- Sponsor
- University Hospital Regensburg
Hypomelanotic Macules, Facial Angiofibroma
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s
- Conditions
- Hypomelanotic Macules, Facial Angiofibroma, Shagreen Patches, Ungual Fibromas
- Trial name
- TuScCom (NCT02654340)
- Where
- 8 sites in Albania, Egypt and 6 more
- Volunteers
- 20 people
- Sponsor
- CENTOGENE GmbH Rostock
Gliomas
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
The primary objective of this study is to evaluate the efficacy of a combined treatment with cilengitide and metronomic oral temozolomide as measured by 6 months overall survival (OS) after diagnosis of relapse or tumour…
- Trial name
- HGG-CilMetro (NCT01517776)
- Testing
- Cilengitide, Temozolomide
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Glioma
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG).
- Trial name
- PBTC-047 (NCT02717455)
- Testing
- LBH589
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Recurrent Glioblastoma
Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma
This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma.
- Trial name
- NCT05201326
- Testing
- Bevacizumab，Irinotecan and Re-radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Surgical Procedure, Unspecified
Intraoperative Fluorescence of Ganglogliomas and Neuroepithelial Dysembryoplastic Tumors
One of the key issues of tumour brain surgeries is to clearly define the borders of the tumor. The investigators proposed to evaluate the feasibility of intraoperative fluorescein guidance.
- Trial name
- FLUOGOD (NCT03970785)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Glioblastoma (GBM)
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients.
- Trial name
- NCT07130149
- Testing
- Sonodynamic Therapy (SDT), Standard Treatment
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yingjuan Zheng
Glioblastoma
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Background: Glioblastoma (GBM) brain tumors almost always return after treatment. When that happens the tumor can never completely be removed by surgery, so most people also receive drugs.
- Trial name
- NCT03493932
- Testing
- Nivolumab, BMS-986016
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.